Africa: PATH Receives Follow-On Funding to Scale Up Production of Thermostable Influenza Vaccines

12 February 2013
press release

Seattle, February 12, 2013--The Strategic Science and Technology group of the Biomedical Advanced Research and Development Authority (BARDA), a division of the US Department of Health and Human Services, has awarded PATH US$2.5 million in follow-on funding to advance the development of thermostable influenza vaccines, helping to extend product shelf life and ease logistics during vaccine introduction and rapid deployment.

The typical stability of subunit and live attenuated influenza vaccines is less than two weeks at 37°C. The lead thermostable H1N1 subunit and live attenuated influenza vaccine (LAIV) formulations developed by PATH and Aridis Pharmaceuticals during an earlier period of project work have proven to be stable at 37°C for over nine months and five months, respectively, which represent significant improvements over the control formulations. Under the new funding from BARDA, the stability of these improved formulations will continue to be monitored by PATH and Aridis Pharmaceuticals over the course of an ongoing two-year study.

...

Tagged:

AllAfrica publishes around 400 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.